CALZF (Polynovo) Total Stockholders Equity: $55.24 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CALZF Polynovo Ltd CALZF
72 GF Score
Price $0.62
GF Value $2.05
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Polynovo Total Stockholders Equity?

Polynovo CALZF +10.71% 72 Total Stockholders Equity is $55.24 Mil as of Dec. 2025. GuruFocus rates CALZF with a GF Score™ of 72/100 and a GF Value™ of $2.05 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Polynovo's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $55.24 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Polynovo's Book Value per Share for the quarter that ended in Dec. 2025 was $0.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Polynovo's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.22.

Polynovo  (OTCPK:CALZF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Polynovo's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(55.243-0)/690.843
=0.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Polynovo's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.858 + 10.227) / 55.243
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polynovo Total Stockholders Equity Related Terms

Polynovo Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Polynovo's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polynovo Total Stockholders Equity Chart

Polynovo Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.09 12.45 43.88 47.89 54.21

Polynovo Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.22 47.89 47.81 54.21 55.24
CALZF
72GF Score
Polynovo Ltd CALZF
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $55.24 Mil mean?
Polynovo (CALZF) has a Total Stockholders Equity of $55.24 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Polynovo and its competitors.
Is Polynovo's Total Stockholders Equity too high?
Polynovo's current Total Stockholders Equity is $55.24 Mil. Overall, Polynovo has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Total Stockholders Equity compare to ABT and SYK?
Polynovo's Total Stockholders Equity of $55.24 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Polynovo and its competitors. Polynovo's current Total Stockholders Equity is $55.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.05, compared to a current price of $0.62 — trading 69.8% below its estimated fair value. The current Total Stockholders Equity is $55.24 Mil. Polynovo's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Polynovo (CALZF), the current Total Stockholders Equity is $55.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Polynovo (CALZF) Overvalued in 2026?

Based on GuruFocus' analysis, Polynovo stock appears to be undervalued. The current stock price of $0.62 is trading 69.8% below its estimated GF Value™ of $2.05. GuruFocus considers Polynovo to be Significantly Undervalued.

Key valuation signals for CALZF:

  • Total Stockholders Equity: $55.24 Mil
  • GF Value™: $2.05 vs. price of $0.62 (69.8% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Polynovo Business Description

Other Exchanges MFJ:GermanyPNV:Australia
Address 320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
72GF Score

Get the complete analysis for CALZF

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.62
Price
$2.05
GF Value